Evidence map›Paper›PMID 39972117›Full record

ArticleLeukemia2025

Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation.

Fumiya Wada, Makoto Iwasaki, Masahiro Hirayama, Koji Kawamura, Katsuji Kaida, Noriko Doki, Hirohisa Nakamae, Yuta Hasegawa, Takahiro Fukuda, Tetsuya Eto and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Donor selection, graft engineering, and dosing oh my!Hematology. American Society of Hematology. Education Program · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Fumiya WadaDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0001-6039-146X
Makoto IwasakiDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-7564-157X
Masahiro HirayamaDepartment of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.ORCID 0000-0002-6850-2782
Koji KawamuraDepartment of Hematology, Tottori University Hospital, Tottori, Japan.
Katsuji KaidaDepartment of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.ORCID 0000-0002-8661-3179
Hirohisa NakamaeDepartment of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan.ORCID 0000-0003-4203-990X
Yuta HasegawaDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Nobuhiro HiramotoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.ORCID 0000-0002-0472-6680
Yumiko MaruyamaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Koji NagafujiDivision of Hematology and Oncology, Department of Medicine, Kurume University Hospital, Kurume, Japan.ORCID 0000-0003-4795-121X
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.ORCID 0000-0002-3631-244X
Jun IshikawaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Toshihiko AndoDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.ORCID 0000-0003-4404-2870
Hideki NakasoneDivision of Emerging Medicine for Integrated Therapeutics (EMIT), Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan.ORCID 0000-0001-5812-9315
Junya KandaDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. jkanda16@kuhp.kyoto-u.ac.jp.ORCID 0000-0002-6704-3633

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effects of donor characteristics on outcomes after T-cell-replete (TCR) haploidentical donor peripheral blood stem cell transplantation (PBSCT) with post-transplant cyclophosphamide (PTCy) or low-dose antithymocyte globulin (ATG) remain unclear. We evaluated the impact in 1,677 patients who received a PTCy protocol (PTCy-haplo; n = 1,107) or low-dose ATG protocol (ATG-haplo; n = 570). A low CD34

Indexed as

Donor SelectionGraft vs Host DiseaseHematologic NeoplasmsPeripheral Blood Stem Cell TransplantationTissue DonorsT-LymphocytesTransplantation, HaploidenticalAdolescentAdultAgedAntilymphocyte SerumChildChild, PreschoolCyclophosphamideFemaleFollow-Up StudiesAntilymphocyte SerumCyclophosphamide

Identifiers

PMID39972117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.